Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Murine Lung Infection Model-Reference-Cited by-同舟云学术

Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Murine Lung Infection Model

Published:2018-11 Issue:11 Volume:62 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Avery Lindsay M.¹,Abdelraouf Kamilia¹,Nicolau David P.¹²

Affiliation:

1. Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA

2. Division of Infectious Diseases, Hartford Hospital, Hartford, Connecticut, USA

Abstract

We evaluated the in vivo efficacy of human-simulated WCK 5222 (cefepime-zidebactam) against cefepime-resistant Acinetobacter baumannii strains ( n = 13) in the neutropenic murine lung infection model. Twelve isolates were meropenem resistant.

Funder

Wockhardt Bio AG

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00948-18

Reference17 articles.

1. Anticipating the Unpredictable: A Review of Antimicrobial Stewardship and Acinetobacter Infections

2. Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia

3. In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria

4. WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant β-lactamases

5. Palwe SR, Biniwale SS, Khande HN, Joshi PR, Bhagwat SS, Patel MV. 2016. Cefepime (FEP) and zidebactam (ZID) mediated dual PBP engagement at sub-MIC concentrations drive cidality against diverse β-lactamase expressing Gram-negatives, abstr 448. ASM Microbe 2016, 16 to 20 June 2016, Boston, MA.

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transcending the challenge of evolving resistance mechanisms in Pseudomonas aeruginosa through β-lactam-enhancer-mechanism-based cefepime/zidebactam;mBio;2023-12-19

2. In vitro synergy of the combination of sulbactam-durlobactam and cefepime at clinically relevant concentrations against A. baumannii, P. aeruginosa and Enterobacterales;Journal of Antimicrobial Chemotherapy;2023-10-16

3. Compassionate use of a novel β-lactam enhancer-based investigational antibiotic cefepime/zidebactam (WCK 5222) for the treatment of extensively-drug-resistant NDM-expressing Pseudomonas aeruginosa infection in an intra-abdominal infection-induced sepsis patient: a case report;Annals of Clinical Microbiology and Antimicrobials;2023-07-05

4. Novel Antimicrobial Agents for Gram-Negative Pathogens;Antibiotics;2023-04-16

5. In Vitro Activity of Two Cefepime-Based Novel Combinations, Cefepime/Taniborbactam and Cefepime/Zidebactam, against Carbapenemase-Expressing Enterobacterales Collected in India;Microbiology Spectrum;2023-04-13